Forest Laboratories, Inc. (NYSE:FRX)

CTrading (29.51) Submitted: 8/16/2007 2:53:19 PM : Start Price: $37.99 FRX Score: -11.75

MFI CAP 88 TOP 50 8/16/07

zimn0016 (69.20) Submitted: 8/10/2007 4:34:42 AM : Start Price: $35.19 FRX Score: -1.45

P/E, PEG, limited drugs for future growth, it's cheap right now

PlumbBank (56.06) Submitted: 6/21/2007 11:50:17 AM : Start Price: $45.95 FRX Score: -19.51

Double dip.

fuckmotleyfool23 (< 20) Submitted: 5/22/2007 5:29:56 AM : Start Price: $51.69 FRX Score: -26.88

Strong earnings growth prospects

MCKInate (97.36) Submitted: 1/23/2007 5:46:06 PM : Start Price: $54.98 FRX Score: -37.36

VL

onahook (< 20) Submitted: 1/11/2007 11:41:15 AM : Start Price: $52.50 FRX Score: -34.46

this has been an agressive pharm and has maintained a fimr and steady growth in tough markets as well as good markets for a number of years mgt is doing something right

NetscribePhrmtcl (92.11) Submitted: 12/7/2006 7:07:38 AM : Start Price: $51.56 FRX Score: -33.95

Forest Laboratories, Inc. develops and manufactures name-brand as well as generic prescription and over-the-counter pharmaceutical products.

Forest Laboratories breathed a sigh of relief as the Federal Court upheld Lexapro’s patent, which expires in March 2012. Forest's Lexapro is the second most prescribed antidepressant in the U.S., after Pfizer's Zoloft. It is a significant achievement for the company as Lexapro contributed 67% of the 2006 sales. Considering the fact that approximately 26.2% of the Americans aged 18 years and above suffer from a diagnosable mental disorder every year, the drug is expected to record strong performance in 2007.

Another strong driver for the company is its drug called Namenda, which grew by 53% in 2006. Namenda is the first product indicated for the treatment of severe Alzheimer's disease and controls approximately 31% of the U.S. Alzheimer’s market. The prospect of this drug appears bright as the market for Alzheimer's disease is expected to expand significantly and surpass the $3 billion mark by 2009.

Forest Laboratories has a creditable product pipeline. By mid-2007, it is expected to produce the results of the clinical study for its investigational drug, Desmoteplase, for the treatment of acute ischemic stroke. The drug’s positive outcome would definitely boost the company’s stock price. However, delay in the launch of drugs like Nebivolol and Orapem due to additional tests and data requested by the FDA is a slight cause of concern. However, growing market for anti-depressants and Alzheimer’s disease will drive the company in 2007.

KevinO3826 (63.14) Submitted: 10/24/2006 11:19:17 PM : Start Price: $48.35 FRX Score: +32.72

Should be retracing now with divergence signals already displayed

Geoff564 (< 20) Submitted: 9/10/2006 2:50:03 PM : Start Price: $47.66 FRX Score: -38.41

Chart indicates strength